samedan logo
 
 
 
spacer
home > ebr > spring 2003 > robotics in pharmaceutical research
PUBLICATIONS
European Biopharmaceutical Review

Robotics in Pharmaceutical Research

'Robot' is a Czech word meaning worker, from the play RUR: Rossums' Universal Robots by the Bohemian writer Karel Capek. The robot has since become an inspiration for science fiction writers and for engineers. Of course the science fiction vision of a robot is a mechanical man, but the reality we see in industry is simply a robotic arm. This is a versatile programmable manipulator, an integration of mechanics, electronics and software, designed interdependently to produce the mechanical equivalent of the computer - an undedicated machine unable to do anything until we program it.

In the pharmaceutical lab it is even less than that definition; the term 'robot' being applied to programmable liquid handlers. Drug development requires the screening of hundreds or thousands of samples and it is in this field that the robot arm is a vital tool. Such an automated screening system is called a 'high-throughput screening' (HTS) system.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
5
     

There are no comments in regards to this article.

spacer
By David N Sands, CEO and Founder of ST Robotics International

David N Sands was educated in London. He founded Sands-Whiteley Research and Development, which concentrated on advanced electronics and industrial automation using mini-computers and later microprocessors. David was a Department of Industry Consultant on microprocessors for many years. In 1982 the first robots were designed and Cyber Robotics, which was later sold to the Bibby Corporation, was formed the same year.

David wrote the first robot software, ROBOFORTH, in 1982 and designed the first robot controller in 1985. In 1989 he formed Sands Technology with Catherine George and ST-Monforte Robotics with Mathew Monforte in Trenton, New Jersey, in 1991. Sands Technology International Inc was formed in 1992 with Mathew Monforte as Vice President.
 

spacer
David N Sands
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nordic Capital acquires specialty pharmaceutical company Advanz Pharma in deal worth ~$846 million

The acquisition will bring significant investment and expertise to help fuel ADVANZ PHARMA’s growth, with the potential to bring further cost-savings to the NHS and wider European healthcare systems while enhancing choice and access to critical medicines globally.
More info >>

White Papers

Cold-chain Bioprocessing Readiness: Mitigating Risk and Protecting Pharmaceutical Products

Entegris

The pharmaceutical industry is migrating rapidly toward a world where drugs, vaccines, and specialized therapies are available on demand to patients anywhere around the globe. Whether accelerating clinical trials to bring new drugs to market or devel oping biosimilars to give more patients access to established commercial drugs, small and midsize production facilities stand to benefit from growing demand. To do so, however, they must be prepared to handle a broader mix of products and increase throughput without sacrificing safety or reliability, while at the same time keeping life-saving medica tions affordable. Such challenges become more difficult when working with products that must be stored and shipped in a frozen state.
More info >>

 
Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement